Coherus BioSciences Announces New Employment Inducement Grants
April 19 2018 - 4:45PM
Coherus BioSciences, Inc. (Nasdaq:CHRS), today announced that
effective April 19, 2018, the compensation committee of the
company’s board of directors granted 9 new employees options to
purchase an aggregate of 187,000 shares of the company’s common
stock with a per share exercise price of $12.05, the closing
trading price on the grant date. The stock options were
granted pursuant to the Coherus BioSciences, Inc. 2016 Employment
Commencement Incentive Plan, which was approved by the company’s
board of directors in June 2016 under Rule 5635(c)(4) of the Nasdaq
Global Select Market for equity grants to induce new employees to
enter into employment with the company.
About Coherus BioSciences, Inc.Coherus is a
leading pure-play, global biosimilar company that develops and
commercializes high-quality therapeutics for major regulated
markets. Biosimilars are intended for use in place of existing,
branded biologics to treat a range of chronic and often
life-threatening diseases, with the potential to reduce costs and
expand patient access. Composed of a team of proven industry
veterans with world-class expertise in process science, analytical
characterization, protein production, sales & marketing and
clinical-regulatory development, Coherus is positioned as a leader
in the global biosimilar marketplace. Coherus is advancing three
late-stage clinical products towards commercialization, CHS-1701
(pegfilgrastim biosimilar), CHS-1420 (adalimumab biosimilar) and
CHS-0214 (etanercept biosimilar), as well as developing a robust
pipeline of future products in four therapeutic areas, oncology,
immunology (anti-TNF), ophthalmology including CHS-3351
(ranibizumab biosimilar) and CHS-2020 (aflibercept biosimilar), and
CHS-131, a small molecule for multiple sclerosis. For
additional information, please visit www.coherus.com.
CONTACT:Patrick O’BrienSenior Vice President, Investor
RelationsCoherus BioSciences, Inc.pobrien@coherus.com+1 (650)
649-3527
Coherus BioSciences (NASDAQ:CHRS)
Historical Stock Chart
From Mar 2024 to Apr 2024
Coherus BioSciences (NASDAQ:CHRS)
Historical Stock Chart
From Apr 2023 to Apr 2024